Facebook
Twitter
LinkedIn
ForwardRecordings from 2022 Summit on Cancer Health Disparities (SCHD22)
This accredited continuing education activity “Webcast-2022 Summit on Cancer Health Disparities”, is recorded from the live meeting held on 4/29/22 to 5/1/22 in Seattle, WA.
If you participated in the live meeting titled - 2022 Summit on Cancer Health Disparities on 4/29/2021-5/1/2022 and claimed CME credits for that activity, you do not qualify for CME credits for your participation in this enduring activity. This is a recorded content from that meeting on 4/29/2021-5/1/2022. However, you may enroll in this activity to review the contents.
The recorded lectures and subsequent discussions features lectures, panel discussions, and debates among leaders across the spectrum of cancer care delivery discussing the factors leading to cancer health disparities and ways to overcome the impact of these factors to optimize outcomes of cancer patients.
The goal of this activity was to foster collaborative interdisciplinary interactions and partnerships to stimulate the development of new research and clinical practices that reduce cancer health disparities and improve outcomes of the diverse patient population.
REGISTRATION FEES:
Registration fee for this activity is $0 for everybody.
Target Audience
- Oncologist and Hematologists
- Oncology and Hematology Nurse Practitioners
- Oncology and Hematology Physician Assistants
- Oncology and Hematology Nurses
- Oncology and Hematology Pharmacists
- Oncology and Hematology Fellows/Residents
- Oncology and Hematology Researchers
- Others interested in cancer disparities
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Identify drivers of cancer health disparities and review their impact on patients along the cancer continuum.
- State the financial and physical barriers, review strategies to navigate these factors to optimize management of patients with cancer.
- Incorporate evidence-based strategies to minimize the impact of specific drivers of inequity in the management of patients with cancer.
- Describe challenges and develop novel approaches to improve participation of underrepresented communities in clinical trials.
This educational activity features recorded videos from the live webinar titled - 2022 Summit on Cancer Health Disparities held 4/29/2022-5/1/2022.
The videos are placed in the following order. Feel free to view the content that is relevant to you.
Participants should claim continuing education credits to the extent of their participation.
15 minutes - Access to insurance and access to cancer care - Dr. Amy Davidoff
15 minutes - ACA and access to cancer care - Dr. Richard Goss
15 minutes - Experience from a county hospital - Dr. Hannah Linden
20 minutes - Panel discussion / Q&A
15 minutes - Career in cancer care disparities - Dr. Narjust Duma
25 minutes - Funding opportunities for disparities research - Dr. Edith Mitchell
25 minutes - Panel discussion - Dr. Manali Indravadan Patel, Dr. Molly Tokaz, Dr. Lisa Tachiki
15 minutes - Access to care by practice setting - Keynote Speech - Dr. Ana Maria Lopez
50 minutes - Panel discussion - Dr. Shailender Bhatia, Dr. Joseph Rosales, Dr. Michael Wagner, Dr. Sibel Blau
20 minutes - Telemedicine for cancer care after the COVID-19 pandemic: lessons learned - Dr. Jack West
20 minutes - Project ECHO and delivering global oncology - Dr. Ellen Baker
15 minutes - Asynchronous integration of an oncology subspecialist with local delivery of cancer care: The AccessHope experience - Dr. Afsaneh Barzi
15 minutes - Lancet Commission on Women and Cancer - Dr. Ophira Ginsburg
20 minutes - WHO Global Breast Cancer Initiative - Dr. Ben Anderson
15 minutes - Overcoming Racial, Ethnic, and Socioeconomic Disparities in Breast Cancer Care in the US - Dr. Edith Mitchell
10 minutes - ASCO's efforts in improving access to cancer care - Dr. Everett Vokes
10 minutes - ASCP's efforts in improving access to cancer care - Dr. Danny A. Milner, Jr
10 minutes - EONS' efforts in improving access to cancer care - Johan deMunter
10 minutes - ASTRO’S efforts in improving access to cancer care - Dr. Geraldine Jacobson
10 minutes - NCCN'S efforts in improving access to cancer care - Dr. Robert W. Carlson
20 minutes - Panel discussion
30 minutes - Anal cancer screening among people living with HIV: Lessons from the ANCHOR study - Dr. Joel Palefsky
20 minutes - Cultural barriers to equity and cancer disparities among sexual and gender minorities - Dr. Matthew Schabath
20 minutes - Cancer screening among women living with HIV - Dr. Liz Chiao
20 minutes - Cancer Health Disparities in the LGBTQ population panel discussion - Bakari Salim and Michael Louella
15 minutes - The promise of Universal Health Coverage (UHC) for global cancer: moving from challenges to solutions - Dr. Richard Sullivan
15 minutes - Levelling the field in cancer research to control global cancer burden - Dr. Nazik Hammad
15 minutes - Founding of cancer care and research institute in Jamaica - Dr. Dingle Spence
5 minutes - Global Oncology panel discussion - Dr. Manoj P. Menon
20 minutes - Clinical Trials and Disparities in cancer care key note speech - Dr. Joseph Unger
55 minutes - Panel discussion - Dr. Mark Pegram, Dr. Shilpen Patel, and Dr. Mark Lewis
15 minutes - Globalization of Precision Oncology: Future outlook and challenges - Dr. Vivek Subbiah
10 minutes - Implementation of Precision medicine in Lung Cancer: Challenges - Dr. Rafael Santana-Davila
10 minutes - Precision Medicine in Bladder Cancer: Challenges and opportunities - Dr. Petros Grivas
10 minutes - Health Economics of Precision Oncology - Dr. Dipesh Uprety
15 minutes - Genetics and high risk hereditary cancers and Precision Medicine: Challenges - Dr. Marianne Dubard-Gault
Expediting adoption of practice-changing research in community practice - current challenges and potential solutions
15 minutes - Plenary lecture - Dr. Nancy E. Davidson
20 minutes - Plenary lecture - Dr. Wui-Jin Koh
30 minutes - Panel discussion - Dr. Edward L. Briercheck, Dr. Tony Blau
70 minutes - Imaging in LMIC panel discussion - Dr. Farouk Dako, Dr. Ravi Shrestha, Dr. Chiranjiv Singh, and Dr. Norissa Haynes
No members of the planning committee have any relevant financial relationship with ineligible companies. All relevant financial relationship for planners and faculty of this activity have been identified and mitigated.
Amy Davidoff, PhD, MS has a financial relationship (Independent contractor) with Amgen.
Rachel Yung, MD has no relevant financial relationships to disclose at this time.
Bridgette Hempstead has no relevant financial relationships to disclose at this time.
Petros Grivas, MD, PHD has a financial relationship (Independent contractor) with Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Seattle Genetics, Pfizer, Janssen, Mirati Therapeutics, Exelixis, Roche, Genentech, Dyania Health, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, Regeneron Pharmaceuticals, Astellas Pharma, Guardant Health, Urogen pharma, Gilead Sciences, Silverback Therapeutics; financial relationship (Grant or Contract) with Research funding to the institution: Pfizer, Clovis Oncology, Bavarian Nordic, Bristol-Myers Squibb, Debiopharm Group, Merck, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics, EMD Serono, G1 Therapeutics, Gilead Sciences.
Richard Goss, MD has no relevant financial relationships to disclose at this time.
Afsaneh Barzi, MD, PHD has no relevant financial relationships to disclose at this time.\
Hannah Linden, MD has a financial relationship (Grant or Contract) with GE, Sanofi, Veru, Zeno, Tolmar.
MODERATOR(S)
David Aboulafia, MD has no relevant financial relationships to disclose at this time.
Chandrikha Chandrasekharan, MBBS has no relevant financial relationships to disclose at this time.
Julie Gralow, MD has no relevant financial relationships to disclose at this time.
Natasha Hunter, MD has no relevant financial relationships to disclose at this time.
Shaji Kumar, MD has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen, Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene; financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen, Janssen, , Astra-Zeneca, Novartis, Roche-Genentech, Takeda, Tenebio, Molecular Templates.
Chadi Nabhan, MD MBA has no relevant financial relationships to disclose at this time.
Howard (Jack) West, MD has a financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with Regeneron; financial relationship (Independent contractor) with Mirati; financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Genentech/Roche; financial relationship (Independent contractor) with Takeda.
GHASSAN ABOU-ALFA, MD has a financial relationship (Independent contractor) with Adicet, Alnylam, Astra Zeneca, Autem, Bayer, Beigene, Berry Genomics, Eisai, Exelixis, Flatiron, Genentech/Roche, Genoscience, Helio, Incyte, Ipsen, Legend Biotech, Merck, Nerviano, QED, Redhill, Servier, Surface Oncology, Therabionics, Vector, Yiviva; financial relationship (Grant Or Contract) with Arcus, Agios, Astra Zeneca, BioNtech, BMS, Celgene, Flatiron, Genentech/Roche, Genoscience, Incyte, Polaris, Puma, QED, Silenseed, Yiviva; financial relationship (Independent contractor) with Astra Zeneca, Celgene, Cend, CytomX, Eli Lilly, Merck, Rafael, Silenseed, Sobi.
Benjamin Anderson has no relevant financial relationships to disclose at this time.
Ellen Baker, MD, MPH has no relevant financial relationships to disclose at this time.
C. Anthony Blau has no relevant financial relationships to disclose at this time.
Sibel Blau, MD has no relevant financial relationships to disclose at this time.
Edward Briercheck, MD/PhD has no relevant financial relationships to disclose at this time.
Robert Carlson, MD has no relevant financial relationships to disclose at this time.
Elizabeth Chiao, M.D., M.P.H. has no relevant financial relationships to disclose at this time.
Farouk Dako, MD, MPH has no relevant financial relationships to disclose at this time.
Nancy Davidson, MD has no relevant financial relationships to disclose at this time.
Johan De Munter, RN, PgCert has no relevant financial relationships to disclose at this time.
Marianne Dubard-Gault, MD, MS has no relevant financial relationships to disclose at this time.
Narjust Duma, MD has a financial relationship (Independent contractor) with Pfizer; financial relationship (Independent contractor) with Inivata/Neogenomics; financial relationship (Independent contractor) with Astrazeneca; financial relationship (Independent contractor) with Janssen; financial relationship (Independent contractor) with BI oncology; financial relationship (Independent contractor) with BMS; financial relationship (Independent contractor) with Nexus Oncology.
JOSEPHINE FELICIANO, MD has no relevant financial relationships to disclose at this time.
Nazik Hammad, M.D., M.Sc., MEHP, FACP has no relevant financial relationships to disclose at this time.
Norrisa Haynes, MD, MPH, MSHP has no relevant financial relationships to disclose at this time.
Geraldine Jacobson, MD, MPH, MBA has no relevant financial relationships to disclose at this time.
Mark Lewis, M.D. has a financial relationship (Professional Services) with Foundation Medicine; financial relationship (Professional Services) with QED; financial relationship (Professional Services) with Medscape; financial relationship (Professional Services) with Ipsen; financial relationship (Professional Services) with Natera; financial relationship (Professional Services) with HalioDx; financial relationship (Professional Services) with AstraZeneca/Daiichi Sankyo; financial relationship (Professional Services) with Exelixis; financial relationship (Professional Services) with TerSera.
Ana Maria Lopez, MD, MPH has no relevant financial relationships to disclose at this time.
Michael Louella, BS has no relevant financial relationships to disclose at this time.
Manoj Menon, MD, MPH has no relevant financial relationships to disclose at this time.
Danny Milner, Jr, MD, MSc, MBA has no relevant financial relationships to disclose at this time.
Edith Mitchell, MD, MACP, FCCP, FRCP has a financial relationship (Other) with Genentech; financial relationship (Other) with Astellas; financial relationship (Other) with SEMA4; financial relationship (Other) with Amgen; financial relationship (Other) with Bristol, Myers, Squibb; financial relationship (Other) with Corvus.
Chadi Nabhan, MD MBA has no relevant financial relationships to disclose at this time.
Salim Nganzi, Mr has no relevant financial relationships to disclose at this time.
Joel Palefsky, MD has a financial relationship (Professional Services) with Antiva Bioscience; financial relationship (Stock Options) with Virion Therapeutics; financial relationship (Professional Services) with Vir Biotechnology; financial relationship (Professional Services) with Merck and Co.
Aparna Parikh, MD has a financial relationship (Other) with C2i genomics; financial relationship (Other) with Eli Lilly; financial relationship (Other) with Roche; financial relationship (Other) with Pfizer .
Manali Patel, MD, MPH, MS has no relevant financial relationships to disclose at this time.
Shilpen Patel, MD, FACRO FASTRO has a financial relationship (Employment) with Genentech.
Mark Pegram, MD has no relevant financial relationships to disclose at this time.
Joseph Rosales, MD has no relevant financial relationships to disclose at this time.
Rafael Santana-Davila, MD has no relevant financial relationships to disclose at this time.
Matthew B. Schabath, PhD has no relevant financial relationships to disclose at this time.
Ravi Bickram Shrestha PhD, DIC, ACGI, FFBA has a financial relationship (Employment) with Canon Medical.
Rachna Shroff, MD has a financial relationship (Professional Services) with Novocure; financial relationship (Professional Services) with Taiho; financial relationship (Professional Services) with AstraZeneca; financial relationship (Professional Services) with Incyte; financial relationship (Professional Services) with Taiho; financial relationship (Professional Services) with Bristol-Myers; financial relationship (Professional Services) with LOXO; financial relationship (Professional Services) with Seagen; financial relationship (Professional Services) with Genentech; financial relationship (Professional Services) with Servier; financial relationship (Professional Services) with BMS; financial relationship (Professional Services) with Rafael Pharm; financial relationship (Professional Services) with Clovis; financial relationship (Professional Services) with QED Therapeutics; financial relationship (Professional Services) with Bayer; financial relationship (Professional Services) with IMV Inc.; financial relationship (Professional Services) with NUCANA; financial relationship (Professional Services) with Boehringer Ingelheim; financial relationship (Professional Services) with Merck; financial relationship (Professional Services) with Zymeworks; financial relationship (Professional Services) with Exelixis .
Chiranjiv Singh has a financial relationship (Employment) with Qure.ai Technologies Inc.
Bhawna Sirohi, MBBS, FRCP has no relevant financial relationships to disclose at this time.
Dingle Spence, MBBS, Dip Pall Med, FRCR has no relevant financial relationships to disclose at this time.
Vivek Subbiah, MD has a financial relationship (Grant Or Contract) with Blueprint Medicines; financial relationship (Grant Or Contract) with Amgen; financial relationship (Grant Or Contract) with LOXO/ Eli Lilly; financial relationship (Grant Or Contract) with Bayer; financial relationship (Grant Or Contract) with Relay Therapeutics; financial relationship (Grant Or Contract) with Novartis.
Richard Sullivan has no relevant financial relationships to disclose at this time.
Lisa Tachiki, MD has no relevant financial relationships to disclose at this time.
Molly Tokaz has no relevant financial relationships to disclose at this time.
Joseph Unger has no relevant financial relationships to disclose at this time.
Dipesh Uprety, MD, FACP has a financial relationship (Professional Services) with Daiichi Sankyo, Astrazeneza, and Sanofi..
Everett Vokes, MD has a financial relationship (Financial Support) with Beigene; financial relationship (Financial Support) with Genentech; financial relationship (Financial Support) with AstraZeneca; financial relationship (Financial Support) with EMD Serono; financial relationship (Financial Support) with Novartis; financial relationship (Financial Support) with AbbVie; financial relationship (Financial Support) with Eli Lilly; financial relationship (Financial Support) with Merck; financial relationship (Financial Support) with BioNTech; financial relationship (Financial Support) with GlaxoSmithKline.
Michael Wagner, M.D. has a financial relationship (Independent contractor) with Epizyme; financial relationship (Independent contractor) with Deciphera; financial relationship (Independent contractor) with Adaptimmune.
Howard (Jack) West, MD has a financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Takeda; financial relationship (Independent contractor) with Genentech/Roche; financial relationship (Independent contractor) with Regeneron; financial relationship (Independent contractor) with AstraZeneca; financial relationship (Independent contractor) with Mirati.
Siddhartha Yadav, MD, FACP has no relevant financial relationships to disclose at this time.
Important Information about Claiming CME for this activity:
If you participated in the live meeting titled - 2022 Summit on Cancer Health Disparities on 4/29/2022-5/1/2022 and claimed CME credits for that activity, you do not qualify for CME credits for your participation in this enduring activity. This is a recorded content from that meeting on 4/29/2022-5/1/2022. However, you can still enroll in this activity and review the contents as needed.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
The live portion of this activity and all associated enduring materials are supported with independent medical education grants from the following companies:
- Novartis Pharmaceuticals.
- Janssen Scientific Affairs, LLC
- Pfizer, Inc.
- Merck Sharp & Dohme
- AstraZeneca
BCRF SPONSORSHIP
We would like to thank the Breast Cancer Research Foundation for sponsoring the Breast Cancer Disparities Session.
Available Credit
- 11.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 11.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.